Literature DB >> 7930032

Once daily dosing of netilmicin in neonatal and pediatric intensive care.

B P Wagner1, J Pfenninger.   

Abstract

OBJECTIVE: To examine a once daily dosing regimen of netilmicin in critically ill neonates and children. DESIGN AND
SETTING: Open, prospective study on 81 antibiotic courses in 77 critically ill neonates and children, hospitalized in a multidisciplinary pediatric/neonatal intensive care unit. For combined empiric therapy (aminoglycoside and beta-lactam), netilmicin was given intravenously over 5 min once every 24 h. The dose ranged from 3.5-6 mg/kg, mainly depending upon gestational and postnatal age. Peak levels were determined by immunoassay 30 min after the second dose and trough levels 1 h before the third and fifth dose or after adaptation of dosing.
RESULTS: All peak levels (n = 28) were clearly above 12 mumol/l (mean 22, range 13-41 mumol/l). Eighty-nine trough levels were within desired limits (< 4 mumol/l) and 11 (11%) above 4 mumol/l, mostly in conjunction with impaired renal function.
CONCLUSIONS: Optimal peak and trough levels of netilmicin can be achieved by once daily dosing, adapted to gestational/postnatal age and renal function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7930032     DOI: 10.1007/bf01720910

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  10 in total

1.  Once daily dosing of aminoglycoside: one step forward.

Authors:  J C Pechère; W A Craig; F Meunier
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

2.  Once-daily dosing decreases renal accumulation of gentamicin and netilmicin.

Authors:  G A Verpooten; R A Giuliano; L Verbist; G Eestermans; M E De Broe
Journal:  Clin Pharmacol Ther       Date:  1989-01       Impact factor: 6.875

3.  Serum netilmicin levels in premature AGA infants.

Authors:  L Cordero; L Arwood; S DeCenzo; J Visconti
Journal:  Am J Perinatol       Date:  1987-01       Impact factor: 1.862

4.  The postantibiotic effect.

Authors:  W A Craig; B Vogelman
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

5.  Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage.

Authors:  A W Sturm
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

6.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Authors:  R D Moore; P S Lietman; C R Smith
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

7.  Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin.

Authors:  P M Tulkens
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

8.  Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations.

Authors:  K Fattinger; S Vozeh; A Olafsson; J Vlcek; M Wenk; F Follath
Journal:  Clin Pharmacol Ther       Date:  1991-07       Impact factor: 6.875

9.  Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model.

Authors:  A U Gerber; S Kozak; C Segessenmann; U Flückiger; T Bangerter; U Greter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-03       Impact factor: 3.267

10.  Reference ranges for plasma creatinine during the first month of life.

Authors:  P T Rudd; E A Hughes; M M Placzek; D T Hodes
Journal:  Arch Dis Child       Date:  1983-03       Impact factor: 3.791

  10 in total
  4 in total

Review 1.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

2.  Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very low gestational age.

Authors:  Jens Rengelshausen; Bernd Beedgen; Konstantina Tsamouranis; Gerd Mikus; Ingeborg Walter-Sack; Walter E Haefeli; Otwin Linderkamp
Journal:  Eur J Clin Pharmacol       Date:  2006-07-25       Impact factor: 2.953

3.  Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients.

Authors:  Donna M Kraus; Manjunath P Pai; Keith A Rodvold
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

4.  Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature.

Authors:  Stan J F Hartman; Roger J Brüggemann; Lynn Orriëns; Nada Dia; Michiel F Schreuder; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2020-02       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.